MedTrace Logo

Bevacizumab, Dacarbazine and Interferon-Alfa to Treat Metastatic Melanoma

NCT00308607 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 27

Last updated 2009-04-03

No results posted yet for this study

Summary

The purpose of this study is to determine whether combination therapy with bevacizumab (Avastin), dacarbazine and interferon-alfa-2a (Roferon-A) is effective in patients with locally advancing or metastatic melanoma.

Conditions

Interventions

DRUG

Bevacizumab (Avastin)

DRUG

dacarbazine

DRUG

interferon-alfa-2a (Roferon-A)

Sponsors & Collaborators

  • University of Turku

    lead OTHER

Principal Investigators

  • Pia P Vihinen, MD, PhD · Turku University Hospital, Department of Oncology and Radiotherapy, Savitehtaankatu 1, FIN-20520 Turku, Finland

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-08-31
Primary Completion
2008-12-31
Completion
2009-04-30

Countries

  • Finland

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00308607 on ClinicalTrials.gov